Aminoacyl tRNA synthetase

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

Retrieved on: 
Thursday, July 29, 2021

11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.

Key Points: 
  • 11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.
  • ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases.
  • These patents encompassed important new therapeutic modalities which underpin the broad pipeline of novel therapeutics in active development at the company.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases.

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 6, 2021

b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyr\xe2\x80\x99s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

Retrieved on: 
Tuesday, March 16, 2021

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 11, 2021

Details of the poster presentations are as follows:

Key Points: 
  • Details of the poster presentations are as follows:
    Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • In many forms of cancer, high NRP2 expression is associated with worse outcomes.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

Retrieved on: 
Thursday, February 11, 2021

SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has initiated two new discovery programs from its tRNA synthetase platform.

Key Points: 
  • SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has initiated two new discovery programs from its tRNA synthetase platform.
  • These programs will investigate the functionality of selected fragments of Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) in immunology, fibrosis and cancer.
  • The discovery programs will utilize the companys novel approach to identifying target receptors for tRNA synthetase fragments to help characterize the mechanism of action of these proteins.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

Retrieved on: 
Friday, January 22, 2021

Research approach led to the identification of target receptors for two tRNA synthetases and further validates companys biology platform.

Key Points: 
  • Research approach led to the identification of target receptors for two tRNA synthetases and further validates companys biology platform.
  • The poster describes a mass spectrometry proteomics-based approach to identify target receptors for two distinct extracellular tRNA synthetase fragments.
  • Furthermore, this approach can be applied more broadly to identify receptor targets of extracellular proteins and other ligands such as peptides, antibodies or viruses.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.

aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

Retrieved on: 
Thursday, January 7, 2021

The presentation will be available for on-demand access starting Monday, January 11, 2021, at 6:00am ET.

Key Points: 
  • The presentation will be available for on-demand access starting Monday, January 11, 2021, at 6:00am ET.
  • Company management will also participate in virtual one-on-one meetings with registered attendees of the partnering system hosted by the Biotechnology Innovation Organization (BIO) during the J.P. Morgan Healthcare Conference week from January 11-15, 2021.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Publication in the Journal mAbs

Retrieved on: 
Wednesday, November 11, 2020

The paper, titled Isolation of monoclonal antibodies from anti-synthetase syndrome patients and affinity maturation by recombination of independent somatic variants, was published in the peer-reviewed journal mAbs.

Key Points: 
  • The paper, titled Isolation of monoclonal antibodies from anti-synthetase syndrome patients and affinity maturation by recombination of independent somatic variants, was published in the peer-reviewed journal mAbs.
  • The research was conducted in collaboration with, AbCellera Biologics, Inc., a leader in antibody technology and discovery platforms, who served as a co-author of the publication.
  • aTyr is leveraging its tRNA synthetase biology platform to determine novel pathways mediated through extracellular response.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

Retrieved on: 
Tuesday, November 10, 2020

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has identified receptor targets for two tRNA synthetases from its pipeline.

Key Points: 
  • SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has identified receptor targets for two tRNA synthetases from its pipeline.
  • The receptor targets may have utility in the development of new therapeutics to treat cancer and fibrosis.
  • Human tRNA synthetases play a role in extracellular responses in certain disease states, including cellular stress and tissue homeostasis.
  • We are pleased to advance our knowledge of this newly discovered area of biology by identifying these receptor targets.